More Articles

Market access for biopharmaceuticals and biosimilars: a case study Biosimilars/Research | Posted 26/11/2010

Filgrastim is one of the first biopharmaceuticals for which biosimilars have entered the market. This case study illustrates the health economic challenges and the issues that arose in the R &...

The case for health economic studies on biopharmaceuticals Biosimilars/Research | Posted 26/11/2010

In the not too distant future, patents will expire on some major biopharmaceuticals, such as interferons, insulins and granulocyte-colony stimulating factors [1]. This is likely to lead to the mark...

Biopharmaceuticals: the start of personalised medicine Biosimilars/Research | Posted 26/11/2010

Biopharmaceuticals typically bind to their biological target, e.g. a protein linked to a disease [1]. Therefore, a biopharmaceutical is likely to be particularly efficacious in a specific subgroup...

Health economic challenges for biosimilars Biosimilars/Research | Posted 26/11/2010

Biopharmaceuticals represent a fast-growing segment of the pharmaceutical market, making up one third of products in the development pipeline and accounting for 9% of pharmaceutical expenditure [1]...

Ranbaxy beats Teva to Alzheimer’s drug Generics/News | Posted 26/11/2010

Aricept (donepezil hydrochloride), Eisai Pharmaceutical’s biggest selling drug, comes off patent in the US in November 2010. Thereafter donepezil hydrochloride may be sold as a generic drug. Teva h...

An ageing population: generics and biosimilars could be the solution Generics/News | Posted 19/11/2010

On 17 October 2010 the European Generic Medicines Association (EGA) organised an event to discuss patient access to affordable treatments and healthcare sustainability in view of an increasingly ag...

Canadians pay almost twice as much as Americans for generics Generics/Research | Posted 19/11/2010

A new study released on 13 October 2010 by the Canadian Fraser Institute finds that Canadians pay far higher prices, in fact almost double, for generic drugs than patients in the US.

Biosimilars’ hurdles in the US Biosimilars/General | Posted 19/11/2010

Europe serves as a model for other countries looking to define their own regulatory approval criteria. However the opposing interests of biosimilar and innovative companies is resulting in delays t...